Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification

Table 1 List of potential biomarker transcripts as detected in Affymetrix analysis.

Affymetrix probe set ID number	Gene name/symbol	Putative function(s)	Increased in 5416 arm	Increased in Control arm
34546_at	Defd Defensin α 4	Corticostatic, Ca channel regulator	10	6
33530_at	CEA CAM 8	Tumor antigen, integral membrane protein.	9	4
37054_at	BPI	Anti-pathogen response	9	4
31859_at	MMP-9	Protease; ECM maintainence	8	2
32821_at	Lipocalin 2	Anti-pathogen response; apoptosis	10	5
34319_at	S100 P	Ca-binding protein	9	3
41249_at	Hypothetical protein FLJ13052	unknown	7	1
1962_at	Liver arginase	Amino acid metabolism	9	3
266_s_at	CD24 antigen	Anti-pathogen response; differentiation of B cells	9	0
31506_s_at	Defensin α 3	Chemotaxis; anti-microbial response	10	4
32275_at	Antileuko-protease	Secreted inhibitor of serine proteases	9	4
115_at	Thromobospondin 1	Blood clotting; angiogenesis	9	3
37149_s_at	Lactoferrin	Iron transport; putative protease	11	5

A brief summary of putative biological function is listed for each gene product. The ID number assigned by Affymetrix to each transcript-specific probe set is also included. The last two columns list the number of patients in which transcript levels were increased at day 56 relative to day 1; total number of patients it 11 for the SU5416 arm and 12 for the control arm.

ISSN: 1471-2407